Page 3 - Wouter Piepers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of ... Oxurion NVApril 7, 2021 GMT Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year Leuven, BE, Boston, MA, US – April 7, 2021 – 05.45 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies for retinal vascular disorders, a...

Oxurion NV Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year Leuven, BE, Boston, MA, US – April 7, 2021 – 05.45 PM CET �...

  First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year   THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020   The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.   At the end of December 2020, Oxurion had cash, cash equiva...

  First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year   THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020   The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.   At the end of December 2020, Oxurion had cash, cash equiva...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.